Product Images Signifor Lar

The text only contains fragmented words and does not provide any useful meaning. Therefore, the description for this text is not-available.*

This text appears to be a description of a medication called Signifor'LAR (pasireotide) in a 10mg dosage. The medication is intended for intramuscular use and comes as an injectable suspension with a diluent prefilled syringe. Each vial contains pasireotide pamoate, which is equivalent to 10mg pasireotide base, and several inactive ingredients, including poly (D, L-lactide-co-glycolide) and mannitol. The medication is refrigerated and should not be frozen. Full prescribing information is available in the package insert. It is manufactured by Novartis Pharma AG in Switzerland and distributed by Recordati Rare Diseases in the USA. It should only be administered by a trained healthcare professional. The rest of the text is not available as it appears to be damaged or unreadable.*

This is a description of a medication called Signifor-LAR (pasireotide) in its 20 mg injectable suspension form containing pasireotide PamOate. The medication is for intramuscular use and should only be administered by a trained healthcare professional. Dosage and administration instructions are included in the package insert. The medication is for single-use only and should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). It comes with one vial containing Signifor® LAR powder, one prefilled syringe containing diluent solution for reconstitution, and one 20G x 1.5'' safety injection needle. Inactive ingredients in the medication include poly(D,L-lactide-co-glycolide) [50-60:40-50], poly(D,L-lactide-co-glycolide)[50:50], mannitol, carboxymethylcellulose sodium, poloxamer 188, and water for injection. The vials are manufactured by Novartis Pharma AG, Basel, Switzerland, and the pre-filled diluent syringes are manufactured by Abbott Biologicals B.V., Olst, The Netherlands. The medication is distributed by Recordati Rare Diseases Inc., Lebanon, NJ 08833 U.S.A. For further information, call 1-800-575-8344.*

Signifor'LAR is an injectable suspension for intramuscular use containing pasireotide. Each vial contains 30 mg of pasireotide base. The package insert should be consulted for full prescribing information, dosage, and administration instructions. It should only be used one time, and each carton includes one vial, one pre-filled syringe, and one safety injection needle. The medication should be removed from the refrigerator and allowed to warm to room temperature before reconstitution. It may be refrigerated but must not be frozen. The product is made in Ireland and distributed by Recordati Rare Diseases Inc. in the USA. For more information, a phone number is available.*

Signifor'LAR (pasireotide) is an injectable suspension for intramuscular use, intended for single use only. Each vial of 40 mg contains pasircotidepamoate equivalent to 40mg pasireotide base. Inactive ingredients include poly(D,L-lactide-co-glycolide)[50-60:40-50] and poly(D,L-lactide-co-glycolide)[50:50]. The diluent prefilled syringe contains mannitol, carboxymethylcellulose sodium, poloxamer 188, and water for Injection. The product should be refrigerated and not frozen. It should only be administered by a trained health care professional. Full prescribing information is available in the package insert. For more information, call 1-800-575-8344.*

Signifor-LAR N P (pasireotide) is a drug that comes as an injectable suspension for intramuscular use. It is available in single-use vials containing pasireotide pamoate equivalent to 60 mg of pasireotide base and inactive ingredients such as poly(D, L-lactide-co-glycolide) and mannitol. The diluent prefilled syringe comes with water, carboxymethylcellulose sodium, and poloxamer 188. The drug should only be administered by a trained healthcare professional, and the injection kit should be removed from the refrigerator and allowed to stand at room temperature for at least 30 minutes before reconstitution. For more information, consult the package insert and call 1-800-575-8344.*

This appears to be a table or chart displaying glucose levels in mg/dL over a period of 12 months. The glucose level starts at 140 mg/dL and drops to 80 mg/dL by the end of the period. There are several data points listed in between, but without further context or labels it is difficult to determine their significance.*

Injection sites are likely being discussed, but the rest of the text is not-available due to errors.*

The text shows a chart with the mean value of standardized IGF-1. The chart has time in months on the x-axis and various values on the y-axis. The values are marked with different symbols and it appears to be comparing an active comparator. The text also states a fold above the upper limit of normal for the assay.*